ARCT Stock Summary and Trading Ideas (Arcturus Therapeutics Holdings | NASDAQ:ARCT)

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

Arcturus Therapeutics Holdings trades on the NASDAQ stock market under the symbol ARCT.

As of March 17, 2026, ARCT stock price declined to $6.53 with 317,226 million shares trading.

ARCT has a beta of 2.32, meaning it tends to be more sensitive to market movements. ARCT has a correlation of 0.14 to the broad based SPY ETF.

ARCT has a market cap of $185.53 million. This is considered a Micro Cap stock.

Last quarter Arcturus Therapeutics Holdings reported $7 million in Revenue and -$1.03 earnings per share. This fell short of revenue expectation by $-7 million and missed earnings estimates by -$.21.

In the last 3 years, ARCT traded as high as $45.00 and as low as $5.85.

The top ETF exchange traded funds that ARCT belongs to (by Net Assets): ARKG, VTI, IWM, VXF, IBB.

ARCT has underperformed the market in the last year with a price return of -53.6% while the SPY ETF gained +20.5%. ARCT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -8.4% and -21.8%, respectively, while the SPY returned -0.9% and -2.2%, respectively.

ARCT support price is $6.35 and resistance is $6.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARCT shares will trade within this expected range on the day.